LAG3 and neoplasm: Besides demonstrating the potential for improved anti-tumor activity of specific T cells through genetic editing of LAG-3, PD-1, and TIM-3, we also monitored the systemic toxicity induced by ATT with genetically edited T cells as compared to control T cells.